← The record

High Fat Formula With Vitamins, Minerals And Trace Elements And Low In Protein And Carbohydrate

Recommended MetabolicRestrictedNot applicable line 💬 consumer voice

Management of a ketogenic diet in patients requiring high fat formula with low protein and carbohydrate content supplemented with vitamins, minerals and trace elements.

6
Submissions
4 resub
2015–23
On the record
ICER range
Cost-min
Cost basis

Decisions on record

4 decisions
  • Meeting Mar 2023 Recommended Ketogenic diet
  • Meeting Jul 2021 Recommended Ketogenic diet
  • Meeting Mar 2021 Recommended Ketogenic diet management conditions
  • Meeting Mar 2021 Recommended Ketogenic diet

Access path

6 submissions · public record
  1. Nov 2015
    Recommended
  2. Nov 2020
    Recommended · restricted

    Evidence: Other → Single-arm

  3. Mar 2021
    Recommended

    Comparator changed: KetoCal 4:1, KetoCal 3:1, KetoCal 4:1 LQ → KetoCal 4:1 LQ RTF

  4. Mar 2021
    Recommended · restricted

    Comparator changed: KetoCal 4:1, KetoCal 3:1, KetoCal 4:1 LQ → KetoCal 4:1 LQ RTF

  5. Jul 2021
    Recommended · restricted

    Listing: Restricted → Authority Required

  6. Mar 2023
    Recommended

    Listing: Authority Required → Restricted

  7. PBS listing · Restricted
RecommendedDeferredNot recommended

From the public summary

Verbatim · PSD text · may span indications
PBAC outcome
6.1 The PBAC recommended that new formulations of high fat formula with vitamins, minerals and trace elements and low in protein and carbohydrate (KetoVie® 3:1, KetoVie® 4:1, KetoVie® Peptide 4:1) continue to be listed on the PBS under the existing conditions of the current formulations.PSD · Mar 2023
6.2 The PBAC noted and supported the NPWP advice that the new formulations are expected to provide a non-inferior clinical benefit for the management of a ketogenic diet.PSD · Mar 2023
Economic analysis
5.16 The minor submission presented a cost-minimisation analysis of KetoVie 3:1 and 4:1 compared with KetoCal products based on the same price per kilojoule of $0.0042 at the AEMP. The equi-effective doses were estimated as the same number of kilojoules per day and the comparison was based on the estimated requirement of 6280 kilojoules per day.PSD · Nov 2020
5.17 The sponsor requested a '''''''% premium price for KetoVie Peptide 4:1 over KetoCal 4:1 with an AEMP of $''''''''''''' per kJ (further details on the price are provided in Table 6). The sponsor argued that the premium price was based on: 9PSD · Nov 2020
Clinical claim
5.3 The submission claimed non-inferior comparative effectiveness and safety of KetoVie Peptide 4:1 compared with Formulation 1 and Formulation 2. Product cost/patient/year: $'''''''''''''''''PSD · Jul 2021
5.4 The estimated product cost/patient/year would be $''''''''''''''''''' based on 12 prescriptions per year at the AEMP of $''''''''''''. The actual cost will vary due to variations in individual patient needs. Estimated PBS utilisation and financial implicationsPSD · Jul 2021
Consumer comments
• The amount of Vitamin A has been lowered to match the levels in KetoVie 4:1 as previous clinician feedback reported some patients on higher calorie volumes approached upper limits of Vitamin A.PSD · Mar 2023
• The amount of Vitamin A has been lowered in the KetoVie 4:1 flavours reformulation to match the levels in KetoVie 4:1 unflavoured as clinician feedback reported some patients on higher calorie volumes approached upper limits of Vitamin A.PSD · Mar 2023

Cost-effectiveness

No economic evaluation conducted; cost-minimisation submission with no change to pricing.

The submission did not present economic or financial evaluations. PSD · 2023
Cost-effectiveness accepted ×3

Decision context

PopulationPatients requiring management of a ketogenic diet with high fat formula, low in protein and carbohydrate, supplemented with vitamins, minerals and trace elements.

Submission history

6 entries
DecidedOutcomeComparatorICEREvidence
Mar 2023 Recommended Cost-minimisation · Cost-minimisation
Jul 2021 Recommended · restricted KetoCal 4:1; modular amino acid-based formulations (Formulation 1 and Formulation 2) Cost-minimisation · Cost-minimisation
Mar 2021 Recommended KetoCal 4:1 LQ RTF Cost-minimisation · Cost-minimisation
Mar 2021 Recommended · restricted Cost-minimisation
Nov 2020 Recommended · restricted KetoCal 4:1, KetoCal 3:1, KetoCal 4:1 LQ Single-arm · Seizure frequency
Nov 2015 Recommended Other

Consumer voice

Jul 2021

No consumer comments were received for this submission.

The PBAC noted that this item received no consumer comments. Consumer comments · PSD

Similar precedents

By decision profile